Provided by Tiger Trade Technology Pte. Ltd.

Liminatus Pharma LLC

5.16
-0.4700-8.35%
Post-market: 5.400.2400+4.65%19:51 EDT
Volume:117.26K
Turnover:639.16K
Market Cap:6.93M
PE:-0.29
High:5.88
Open:5.53
Low:5.15
Close:5.63
52wk High:203.00
52wk Low:4.75
Shares:1.34M
Float Shares:581.43K
Volume Ratio:0.99
T/O Rate:20.17%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-18.0650
EPS(LYR):-21.4999
ROE:--
ROA:-95.65%
PB:23.06
PE(LYR):-0.24

Loading ...

Liminatus Pharma Amends Definitive Merger Agreement with Innocsai to Expand Oncology Cell Therapy Pipeline

THOMSON REUTERS
·
Jul 01

Liminatus Pharma - Innocsai Merger Valued at $320 Mln with $0.2 Per Share Issue Price

THOMSON REUTERS
·
Jul 01

Liminatus Pharma Announces Annual Shareholder Meeting

Reuters
·
Jun 30

Liminatus Pharma issues new warrants for 20,688,000 shares in inducement deal

Reuters
·
Jun 03

Liminatus Pharma Enters Into Warrant Exercise Transaction for $1.9 Million in Gross Proceeds

THOMSON REUTERS
·
Jun 03

Liminatus Pharma appeals Nasdaq delisting notice after missing $50 million market value rule

Reuters
·
May 28

Liminatus Pharma receives Nasdaq delisting notice

TIPRANKS
·
May 22

Liminatus Pharma appeals Nasdaq delisting notice, trading suspension set May 29

Reuters
·
May 22

Liminatus Pharma Announces Nasdaq Delisting Notification

THOMSON REUTERS
·
May 22

NASD Most Active Issues

Dow Jones
·
May 22

Liminatus Pharma agrees to merge with InnocsAI in $320 million stock deal

Reuters
·
May 21

Liminatus Pharma Inc - Innocsai Members to Receive 20% of Future Net Proceeds From Certain Strategic Deals

THOMSON REUTERS
·
May 21

Liminatus Pharma Announces Proposed Merger With Innocsai to Expand Oncology Cell Therapy Pipeline

THOMSON REUTERS
·
May 21

Top Premarket Gainers

MT Newswires Live
·
May 21

Liminatus Pharma Inc - Enters Merger Agreement With Innocsai Llc on May 17, 2026 - SEC Filing

THOMSON REUTERS
·
May 21

Liminatus Pharma Inc - Innocsai Members to Receive 1.6 Bln Shares at $0.20 per Share and 20% Contingent Value Rights - SEC Filing

THOMSON REUTERS
·
May 21

Liminatus Pharma agrees to buy InnocsAI in 1,600,000,000-share deal at $0.2 each

Reuters
·
May 21

Liminatus Pharma Q1 FY26 net loss widens to $1.12 million; operating loss widens 317% to $1.1 million

Reuters
·
May 16

NASD Most Active Issues

Dow Jones
·
Apr 16

Liminatus Pharma FY25 net loss widens to $10.2 million; operating loss narrows to $3 million

Reuters
·
Apr 01